[go: up one dir, main page]

MX2011009167A - Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. - Google Patents

Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.

Info

Publication number
MX2011009167A
MX2011009167A MX2011009167A MX2011009167A MX2011009167A MX 2011009167 A MX2011009167 A MX 2011009167A MX 2011009167 A MX2011009167 A MX 2011009167A MX 2011009167 A MX2011009167 A MX 2011009167A MX 2011009167 A MX2011009167 A MX 2011009167A
Authority
MX
Mexico
Prior art keywords
combinations
treatment
chemotherapeutic agents
inhibitor compounds
phosphoinositide
Prior art date
Application number
MX2011009167A
Other languages
English (en)
Inventor
Allen J Ebens Jr
Lori Friedman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2011009167A publication Critical patent/MX2011009167A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las combinaciones de compuestos inhibidores PI3K que tienen la Formula I y agentes quimioterapéuticos, incluyendo estereoisómeros, isómeros geométricos, tautómeros, metabolitos y sales farmacéuticamente aceptables de lo mismo, son útiles para tratar neoplasias malignas hematopoyéticas. Se describen los métodos para usar tales combinaciones para el diagnóstico in vitro, in situ e in vivo, y la prevención o tratamiento contra tales trastornos en células de mamífero, o afecciones patológicas asociadas. (ver fórmula (I)).
MX2011009167A 2009-03-12 2010-03-11 Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. MX2011009167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15962209P 2009-03-12 2009-03-12
PCT/US2010/026903 WO2010105008A2 (en) 2009-03-12 2010-03-11 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies

Publications (1)

Publication Number Publication Date
MX2011009167A true MX2011009167A (es) 2011-09-15

Family

ID=42236787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009167A MX2011009167A (es) 2009-03-12 2010-03-11 Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.

Country Status (11)

Country Link
US (2) US8536161B2 (es)
EP (1) EP2405916B1 (es)
JP (1) JP5709766B2 (es)
KR (1) KR101781654B1 (es)
CN (1) CN102369011A (es)
AU (1) AU2010224125B2 (es)
BR (1) BRPI1006189A2 (es)
CA (1) CA2753285A1 (es)
IL (1) IL214132A (es)
MX (1) MX2011009167A (es)
WO (1) WO2010105008A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY166446A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
WO2010080996A1 (en) 2009-01-08 2010-07-15 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
US20140213630A1 (en) * 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
KR20180108848A (ko) 2011-04-01 2018-10-04 쿠리스 인코퍼레이션 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제
UY34044A (es) * 2011-04-29 2012-11-30 Sanofi Sa Metodo de tratamiento contra el linfoma con inhibidores de piridopirimidinona de p13k/mtor
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
CN103582479A (zh) 2011-06-03 2014-02-12 霍夫曼-拉罗奇有限公司 用pi3k抑制剂化合物治疗间皮瘤的方法
EP2766011B1 (en) 2011-10-13 2017-09-27 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria in cancer patients
MX357100B (es) * 2011-11-09 2018-06-26 Bristol Myers Squibb Co Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4.
CA2867700A1 (en) * 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
JP6077642B2 (ja) * 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
MX349551B (es) * 2012-10-10 2017-08-02 Hoffmann La Roche Proceso para preparar compuestos tienopirimidinas.
JP6437441B2 (ja) * 2012-11-02 2018-12-12 ティージー セラピューティクス インコーポレイテッド 抗ｃｄ２０抗体およびｐｉ３キナーゼ選択的阻害剤の組み合わせ
US20160022757A1 (en) * 2013-03-15 2016-01-28 Icahn School Of Medicine At Mount Sinai Therapeutic methods for treating solid tumors and related diagnostic methods
CN106456776A (zh) 2014-05-21 2017-02-22 豪夫迈·罗氏有限公司 用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
KR20180012324A (ko) 2015-06-29 2018-02-05 에프. 호프만-라 로슈 아게 타셀리십을 사용하는 치료 방법
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3476949A1 (en) * 2017-10-31 2019-05-01 Centre National De La Recherche Scientifique Prognosis method of multiple myeloma
US11234986B2 (en) 2018-09-11 2022-02-01 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EP3870231A1 (en) * 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
JP7592601B2 (ja) * 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
EP4010326A4 (en) * 2019-09-11 2023-08-16 Ohio State Innovation Foundation KINASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2024123102A1 (ko) * 2022-12-07 2024-06-13 에스케이바이오팜 주식회사 Kras g12d 저해제로서 신규한 3환 화합물 및 이의 용도

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2579479A (en) 1950-01-23 1951-12-25 Syntex Sa delta 1, 4-pregnadiene-17alpha-ol-3-ones
US2670347A (en) 1952-01-08 1954-02-23 American Cyanamid Co Thiophosphoric acid derivatives and method of preparing the same
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US2837464A (en) 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
US2897216A (en) 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3134718A (en) 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5075305A (en) 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Ｐｉ３キナーゼ阻害剤とその製造法
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
AUPO903897A0 (en) 1997-09-08 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Organic boronic acid derivatives
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
CA2435124A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
EP1417976A4 (en) 2001-07-26 2004-09-15 Santen Pharmaceutical Co Ltd AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
CN1571676A (zh) 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
US6894055B2 (en) 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
BR0213734A (pt) 2001-10-30 2004-10-19 Pharmacia Corp Derivados de carboxamida heteroaromático para o tratamento de inflamação
CA2493843C (en) 2002-07-10 2012-04-17 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
CA2489779A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding N.V. Use of compounds for increasing spermatozoa motility
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
AU2007246793B2 (en) 2006-04-26 2013-02-07 F. Hoffmann-La Roche Ag Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor
EP2041139B1 (en) * 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2007329352B2 (en) * 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0717907A2 (pt) 2006-12-07 2013-11-05 Genentech Inc "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
FR2920336B1 (fr) * 2007-09-05 2012-09-28 Eads Europ Aeronautic Defence Methode et dispositif d'analyse des procedes de fabrication de pieces en materiaux composites, par infusion ou injection, et de caracterisation de ces materiaux composites.
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
MY166446A (en) * 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
FR2934492B1 (fr) 2008-07-31 2012-08-17 Hospices Civils Lyon Association d'un ligand de tlr3 et d'un agent agissant sur la voie intrinseque de "l'apoptose" dans le traitement d'un cancer.

Also Published As

Publication number Publication date
KR20110132442A (ko) 2011-12-07
JP2012520313A (ja) 2012-09-06
IL214132A0 (en) 2011-08-31
CN102369011A (zh) 2012-03-07
EP2405916B1 (en) 2018-02-07
JP5709766B2 (ja) 2015-04-30
US8536161B2 (en) 2013-09-17
AU2010224125B2 (en) 2015-05-14
WO2010105008A3 (en) 2010-11-25
IL214132A (en) 2015-02-26
WO2010105008A2 (en) 2010-09-16
KR101781654B1 (ko) 2017-09-25
US20100233164A1 (en) 2010-09-16
BRPI1006189A2 (pt) 2020-08-18
EP2405916A2 (en) 2012-01-18
AU2010224125A1 (en) 2011-08-04
US9335320B2 (en) 2016-05-10
CA2753285A1 (en) 2010-09-16
US20130330765A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
MX2011009167A (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
MX2010002543A (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
TW200801012A (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
PH12013501779A1 (en) Pyrrolopyridines as kinase inhibitors
SG178900A1 (en) Raf inhibitor compounds and methods of use thereof
WO2009111278A3 (en) Raf inhibitor compounds and methods of use thereof
SG10201407781SA (en) Benzoxepin PI3K Inhibitor Compounds And Methods Of Use
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
WO2007027855A3 (en) Raf inhibitor compounds and methods of use thereof
MX2010010659A (es) Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
MX2009005925A (es) Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso.
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
WO2007127175A3 (en) Pharmaceutical compounds
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2009005950A (es) Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
MY164910A (en) Tricyclic pi3k inhibitor compounds and methods of use
PH12014500966A1 (en) Alkylated piperazine compounds as inhibitors of btk activity
PH12012501864A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2006125101A3 (en) Raf inhibitor compounds and methods of use thereof
MX2014005285A (es) Compuestos biciclicos de piperazina.
MX2014001239A (es) Compuestos de pirazolo [3,4-c] piridina y metodos de uso.
SG178986A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use

Legal Events

Date Code Title Description
FG Grant or registration